EX-99.2 3 a2024q3exhibit992.htm EX-99.2

Exhibit 99.2

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			THIRD QUARTER
									Percent Change
Sales to customers by geographic area			2024			2023			Total			Operations			Currency
U.S.			$12,909			11,996			7.6		%	7.6			—
Europe			4,914			4,727			4.0			3.0			1.0
Western Hemisphere excluding U.S.			1,173			1,171			0.3			20.3			(20.0)
Asia-Pacific, Africa			3,475			3,457			0.5			1.5			(1.0)
International			9,562			9,355			2.2			4.6			(2.4)
Worldwide			$22,471			21,351			5.2		%	6.3			(1.1)

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			THIRD QUARTER
									Percent Change
Sales to customers by geographic area (ex. COVID-19 Vaccine)			2024			2023			Total			Operations			Currency
U.S.*			$12,909			11,996			7.6		%	7.6			—
Europe(1)			4,913			4,686			4.8			3.8			1.0
Western Hemisphere excluding U.S.*			1,173			1,171			0.3			20.3			(20.0)
Asia-Pacific, Africa*			3,475			3,457			0.5			1.5			(1.0)
International			9,561			9,314			2.7			5.1			(2.4)
Worldwide			$22,470			21,310			5.4		%	6.5			(1.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1) Refer to supplemental sales information schedules

*No COVID-19 Vaccine Sales

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			NINE MONTHS
									Percent Change
Sales to customers by geographic area			2024			2023			Total			Operations			Currency
U.S.			$37,098			34,435			7.7		%	7.7			—
Europe			15,291			15,448			(1.0)			(0.7)			(0.3)
Western Hemisphere excluding U.S.			3,579			3,383			5.8			21.4			(15.6)
Asia-Pacific, Africa			10,333			10,498			(1.6)			2.8			(4.4)
International			29,203			29,329			(0.4)			3.1			(3.5)
Worldwide			$66,301			63,764			4.0		%	5.6			(1.6)

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			NINE MONTHS
									Percent Change
Sales to customers by geographic area (ex. COVID-19 Vaccine)			2024			2023			Total			Operations			Currency
U.S.*			$37,098			34,435			7.7		%	7.7			—
Europe(1)			15,093			14,375			5.0			5.3			(0.3)
Western Hemisphere excluding U.S.*			3,579			3,383			5.8			21.4			(15.6)
Asia-Pacific, Africa*			10,333			10,498			(1.6)			2.8			(4.4)
International			29,005			28,256			2.7			6.3			(3.6)
Worldwide			$66,103			62,691			5.4		%	7.1			(1.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1) Refer to supplemental sales information schedules

*No COVID-19 Vaccine Sales

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			THIRD QUARTER
												Percent Change
Sales to customers by segment of business						2024			2023			Total			Operations			Currency
Innovative Medicine (1)
U.S.						$	8,871		8,249			7.5		%	7.5			—
International						5,709			5,644			1.2			4.4			(3.2)
						14,580			13,893			4.9			6.3			(1.4)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.						8,871			8,249			7.5			7.5			—
International						5,708			5,603			1.9			5.2			(3.3)
						14,579			13,852			5.2			6.6			(1.4)
MedTech
U.S.						4,038			3,747			7.8			7.8			—
International						3,853			3,711			3.9			5.0			(1.1)
						7,891			7,458			5.8			6.4			(0.6)
U.S.						12,909			11,996			7.6			7.6			—
International						9,562			9,355			2.2			4.6			(2.4)
Worldwide						22,471			21,351			5.2			6.3			(1.1)
U.S.						12,909			11,996			7.6			7.6			—
International						9,561			9,314			2.7			5.1			(2.4)
Worldwide excluding COVID-19 Vaccine (1)						$	22,470		21,310			5.4		%	6.5			(1.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales information schedules.

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			NINE MONTHS
									Percent Change
Sales to customers by segment of business			2024			2023			Total			Operations			Currency
Innovative Medicine (1)
U.S.			$24,993			23,090			8.2		%	8.2			—
International			17,639			17,947			(1.7)			2.1			(3.8)
			42,632			41,037			3.9			5.5			(1.6)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.			24,993			23,090			8.2			8.2			—
International			17,441			16,874			3.4			7.4			(4.0)
			42,434			39,964			6.2			7.9			(1.7)
MedTech
U.S.			12,105			11,345			6.7			6.7			—
International			11,564			11,382			1.6			4.7			(3.1)
			23,669			22,727			4.1			5.7			(1.6)
U.S.			37,098			34,435			7.7			7.7			—
International			29,203			29,329			(0.4)			3.1			(3.5)
Worldwide			66,301			63,764			4.0			5.6			(1.6)
U.S.			37,098			34,435			7.7			7.7			—
International			29,005			28,256			2.7			6.3			(3.6)
Worldwide excluding COVID-19 Vaccine (1)			$66,103			62,691			5.4		%	7.1			(1.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales information schedules.

---

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)			THIRD QUARTER
			2024						2023						Percent Increase (Decrease)
			Amount			Percent to Sales			Amount			Percent to Sales
Sales to customers			$	22,471		100.0			$21,351			100.0			5.2
Cost of products sold			6,963			31.0			6,606			30.9			5.4
Gross Profit			15,508			69.0			14,745			69.1			5.2
Selling, marketing and administrative expenses			5,478			24.3			5,400			25.3			1.4
Research and development expense			4,952			22.0			3,447			16.2			43.7
In-process research and development impairments			—			—			206			1.0
Interest (income) expense, net			(99)			(0.4)			(182)			(0.8)
Other (income) expense, net			1,798			8.0			499			2.3
Restructuring			41			0.2			158			0.7
Earnings before provision for taxes on income			3,338			14.9			5,217			24.4			(36.0)
Provision for taxes on income			644			2.9			908			4.2			(29.1)
Net earnings from Continuing Operations			$2,694			12.0			$4,309			20.2			(37.5)
Net earnings from Discontinued Operations, net of tax			—						21,719
Net earnings			$2,694						$26,028
Net earnings per share (Diluted) from Continuing Operations			$	1.11					$	1.69					(34.3)
Net earnings per share (Diluted) from Discontinued Operations			$	—					$	8.52
Average shares outstanding (Diluted)			2,427.9						2,549.7
Effective tax rate from Continuing Operations			19.3		%				17.4		%
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income from Continuing Operations			$	7,277		32.4			$	8,033		37.6			(9.4)
Net earnings from Continuing Operations			$	5,876		26.1			$	6,777		31.7			(13.3)
Net earnings per share (Diluted) from Continuing Operations			$	2.42					$	2.66					(9.0)
Effective tax rate from Continuing Operations			19.3		%				15.6		%

(1)    See Reconciliation of Non-GAAP Financial Measures.

(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

---

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)			NINE MONTHS
			2024						2023						Percent Increase (Decrease)
			Amount			Percent to Sales			Amount			Percent to Sales
Sales to customers			$	66,301		100.0			$	63,764		100.0			4.0
Cost of products sold			20,343			30.7			19,755			31.0			3.0
Gross Profit			45,958			69.3			44,009			69.0			4.4
Selling, marketing and administrative expenses			16,416			24.8			15,702			24.6			4.5
Research and development expense			11,934			18.0			10,605			16.6			12.5
In-process research and development impairments			194			0.3			255			0.4
Interest (income) expense, net			(433)			(0.7)			(277)			(0.4)
Other (income) expense, net			4,855			7.3			7,055			11.1
Restructuring			192			0.3			433			0.6
Earnings before provision for taxes on income			12,800			19.3			10,236			16.1			25.0
Provision for taxes on income			2,165			3.3			1,042			1.7			107.8
Net earnings from Continuing Operations			$	10,635		16.0			$	9,194		14.4			15.7
Net earnings from Discontinued Operations, net of tax			—						21,910
Net earnings			$	10,635					$	31,104
Net earnings per share (Diluted) from Continuing Operations			$	4.38					$	3.53					24.1
Net earnings per share (Diluted) from Discontinued Operations			$	—					$	8.42
Average shares outstanding (Diluted)			2,429.5						2,603.4
Effective tax rate from Continuing Operations			16.9		%				10.2		%
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income from Continuing Operations			$	23,558		35.5			$	23,574		37.0			(0.1)
Net earnings from Continuing Operations			$	19,296		29.1			$	19,847		31.1			(2.8)
Net earnings per share (Diluted) from Continuing Operations			$	7.94					$	7.62					4.2
Effective tax rate from Continuing Operations			18.1		%				15.8		%

(1)See Reconciliation of Non-GAAP Financial Measures.

(A)NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

			Third Quarter
(Dollars in Millions Except Per Share Data)			2024									2023
Net Earnings from Continuing Operations, after tax- as reported						$2,694						$4,309
Pre-tax Adjustments
Litigation related						2,388						(51)
Intangible Asset Amortization expense						1,171						1,132
COVID-19 Vaccine related costs 1						4						44
Restructuring related 2						47						384
Medical Device Regulation 3						38						74
Acquisition, integration and divestiture related						328						22
(Gains)/losses on securities						(37)						1,005
IPR&D impairments						—						206
Tax Adjustments
Tax impact on special item adjustments 4						(762)						(482)
Tax legislation and other tax related						5						134
Adjusted Net Earnings from Continuing Operations, after tax						$5,876						$6,777
Average shares outstanding (Diluted)						2,427.9						2,549.7
Adjusted net earnings per share from Continuing Operations (Diluted)						$2.42						$2.66
Operational adjusted net earnings per share from Continuing Operations (Diluted)						$2.41

Notes:

1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.

2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.  The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) and $149 million in the fiscal third quarter of 2023 ($424 million Q3 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) and $235 million in the fiscal third quarter of 2023 ($235 million Q3 2023 YTD) primarily includes inventory and instrument reserves related to the market and product exits.

3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed by the end of 2024.

4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

			Nine Months Ended
(Dollars in Millions Except Per Share Data)			2024						2023
Net Earnings from Continuing Operations, after tax- as reported						$10,635						$9,194
Pre-tax Adjustments
Litigation related						5,466						6,986
Intangible Asset Amortization expense						3,355						3,384
COVID-19 Vaccine related costs 1						77						653
Restructuring related 2						207						659
Medical Device Regulation 3						157						223
Acquisition, integration and divestiture related						928						102
(Gains)/losses on securities						374						1,076
IPR&D impairments						194						255
Tax Adjustments
Tax impact on special item adjustments 4						(2,055)						(2,769)
Tax legislation and other tax related						(42)						84
Adjusted Net Earnings from Continuing Operations, after tax						$19,296						$19,847
Average shares outstanding (Diluted)						2,429.5						2,603.4
Adjusted net earnings per share from Continuing Operations (Diluted)						$7.94						$7.62
Operational adjusted net earnings per share from Continuing Operations (Diluted)						$7.94

Notes:

1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.

2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.  The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) and $149 million in the fiscal third quarter of 2023 ($424 million Q3 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) and $235 million in the fiscal third quarter of 2023 ($235 million Q3 2023 YTD) primarily includes inventory and instrument reserves related to the market and product exits.

3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed by the end of 2024.

4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Third quarter 2024 actual vs. 2023 actual

Segments
						Innovative Medicine						MedTech						Total
WW As Reported						4.9		%				5.8		%				5.2		%
U.S.						7.5		%				7.8		%				7.6		%
International						1.2		%				3.9		%				2.2		%
WW Currency						(1.4)						(0.6)						(1.1)
U.S.						—						—						—
International						(3.2)						(1.1)						(2.4)
WW Operational						6.3		%				6.4		%				6.3		%
U.S.						7.5		%				7.8		%				7.6		%
International						4.4		%				5.0		%				4.6		%
Shockwave												(3.1)						(1.1)
U.S.												(4.4)						(1.4)
International												(1.8)						(0.7)
All Other Acquisitions and Divestitures (A&D)						0.1						0.4						0.2
U.S.						0.1						0.8						0.3
International						0.2						0.0						0.1
WW Adjusted Operational Ex A&D						6.4		%				3.7		%				5.4		%
U.S.						7.6		%				4.2		%				6.5		%
International						4.6		%				3.2		%				4.0		%
COVID-19 Vaccine						0.3												0.2
U.S.						0.0												0.0
International						0.8												0.5
WW Adjusted Operational Ex A&D & COVID-19 Vaccine						6.7		%				3.7		%				5.6		%
U.S.						7.6		%				4.2		%				6.5		%
International						5.4		%				3.2		%				4.5		%

Note: Percentages are based on actual, non-rounded figures and may not sum

(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Nine months 2024 actual vs. 2023 actual

Segments
						Innovative Medicine						MedTech						Total
WW As Reported						3.9		%				4.1		%				4.0		%
U.S.						8.2		%				6.7		%				7.7		%
International						(1.7)		%				1.6		%				(0.4)		%
WW Currency						(1.6)						(1.6)						(1.6)
U.S.						—						—						—
International						(3.8)						(3.1)						(3.5)
WW Operational						5.5		%				5.7		%				5.6		%
U.S.						8.2		%				6.7		%				7.7		%
International						2.1		%				4.7		%				3.1		%
Shockwave												(1.3)						(0.5)
U.S.												(2.1)						(0.7)
International												(0.6)						(0.2)
All Other Acquisitions and Divestitures (A&D)						0.1						0.3						0.2
U.S.						0.1						0.7						0.3
International						0.1						0.1						0.1
WW Adjusted Operational Ex A&D						5.6		%				4.7		%				5.3		%
U.S.						8.3		%				5.3		%				7.3		%
International						2.2		%				4.2		%				3.0		%
COVID-19 Vaccine						2.4												1.5
U.S.						0.0												0.0
International						5.3												3.2
WW Adjusted Operational Ex A&D & COVID-19 Vaccine						8.0		%				4.7		%				6.8		%
U.S.						8.3		%				5.3		%				7.3		%
International						7.5		%				4.2		%				6.2		%

Note: Percentages are based on actual, non-rounded figures and may not sum

(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			THIRD QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)
IMMUNOLOGY
US			$3,068						3,193						(3.9)		%	(3.9)		%	—		%
Intl			1,552						1,656						(6.2)			(2.1)			(4.1)
WW			4,621						4,849						(4.7)			(3.3)			(1.4)
REMICADE
US			281						296						(5.4)			(5.4)			—
US Exports(3)			27						38						(28.9)			(28.9)			—
Intl			112						127						(11.5)			(6.5)			(5.0)
WW			419						461						(9.1)			(7.7)			(1.4)
SIMPONI / SIMPONI ARIA
US			299						310						(3.7)			(3.7)			—
Intl			218						319						(31.8)			(23.3)			(8.5)
WW			516						629						(18.0)			(13.6)			(4.4)
STELARA
US			1,770						1,912						(7.5)			(7.5)			—
Intl			906						951						(4.8)			(2.3)			(2.5)
WW			2,676						2,864						(6.6)			(5.7)			(0.9)
TREMFYA
US			691						634						9.1			9.1			—
Intl			316						258						22.6			26.9			(4.3)
WW			1,007						891						13.0			14.3			(1.3)
OTHER IMMUNOLOGY
US			1						2						(45.6)			(45.6)			—
Intl			0						0						—			—			—
WW			1						2						(45.6)			(45.6)			—
INFECTIOUS DISEASES
US			365						360						1.5			1.5			—
Intl			471						500						(5.7)			(5.1)			(0.6)
WW			836						859						(2.7)			(2.4)			(0.3)
COVID-19 VACCINE
US			0						0						—			—			—
Intl			1						41						(97.7)			(98.9)			1.2
WW			1						41						(97.7)			(98.9)			1.2
EDURANT / rilpivirine
US			8						9						(15.8)			(15.8)			—
Intl			323						287						12.3			11.4			0.9
WW			330						297						11.5			10.6			0.9
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US			355						345						2.8			2.8			—
Intl			94						102						(6.9)			(3.0)			(3.9)
WW			449						447						0.6			1.5			(0.9)
OTHER INFECTIOUS DISEASES
US			3						5						(52.2)			(52.2)			—
Intl			53						69						(23.2)			(20.5)			(2.7)
WW			55						74						(25.4)			(22.9)			(2.5)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			THIRD QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
NEUROSCIENCE
US			$1,094						1,036						5.6		%	5.6		%	—		%
Intl			662						706						(6.2)			(3.9)			(2.3)
WW			1,755						1,742						0.8			1.7			(0.9)
CONCERTA / methylphenidate
US			26						57						(55.0)			(55.0)			—
Intl			117						133						(11.9)			(8.5)			(3.4)
WW			142						189						(24.8)			(22.5)			(2.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US			780						730						6.8			6.8			—
Intl			269						299						(10.1)			(8.3)			(1.8)
WW			1,049						1,029						1.9			2.4			(0.5)
SPRAVATO
US			243						154						56.8			56.8			—
Intl			42						29						44.6			47.4			(2.8)
WW			284						183						54.9			55.3			(0.4)
OTHER NEUROSCIENCE
US			46						94						(51.4)			(51.4)			—
Intl			235						245						(4.4)			(2.0)			(2.4)
WW			281						340						(17.4)			(15.7)			(1.7)
ONCOLOGY
US			2,816						2,219						26.9			26.9			—
Intl			2,565						2,313						10.9			14.3			(3.4)
WW			5,380						4,533						18.7			20.5			(1.8)
CARVYKTI
US			258						140						84.9			84.9			—
Intl			27						12						*			*			*
WW			286						152						87.7			87.6			0.1
DARZALEX
US			1,684						1,369						23.0			23.0			—
Intl			1,332						1,130						17.9			22.8			(4.9)
WW			3,016						2,499						20.7			22.9			(2.2)
ERLEADA
US			337						288						17.1			17.1			—
Intl			453						342						32.4			34.0			(1.6)
WW			790						631						25.4			26.3			(0.9)
IMBRUVICA
US			259						264						(1.9)			(1.9)			—
Intl			494						545						(9.2)			(7.2)			(2.0)
WW			753						808						(6.8)			(5.5)			(1.3)
TECVAYLI
US			105						93						13.5			13.5			—
Intl			30						19						54.2			59.4			(5.2)
WW			135						112						20.6			21.4			(0.8)
ZYTIGA / abiraterone acetate
US			5						16						(66.0)			(66.0)			—
Intl			144						199						(27.1)			(24.4)			(2.7)
WW			150						214						(30.0)			(27.5)			(2.5)
OTHER ONCOLOGY
US			168						50						*			*			—
Intl			83						67						24.8			27.6			(2.8)
WW			250						117						*			*			*

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			THIRD QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
PULMONARY HYPERTENSION
US			$	815					680						20.0		%	20.0		%	—		%
Intl			287						274						4.5			9.7			(5.2)
WW			1,102						954						15.6			17.0			(1.4)
OPSUMIT
US			406						323						25.4			25.4			—
Intl			165						166						(0.2)			1.7			(1.9)
WW			571						490						16.8			17.4			(0.6)
UPTRAVI
US			379						336						12.7			12.7			—
Intl			80						66						21.8			28.2			(6.4)
WW			458						402						14.2			15.2			(1.0)
OTHER PULMONARY HYPERTENSION
US			32						20						54.0			54.0			—
Intl			40						42						(3.9)			12.4			(16.3)
WW			72						63						15.0			25.9			(10.9)
CARDIOVASCULAR / METABOLISM / OTHER
US			713						763						(6.5)			(6.5)			—
Intl			170						194						(11.9)			(10.0)			(1.9)
WW			884						957						(7.6)			(7.2)			(0.4)
XARELTO
US			592						625						(5.2)			(5.2)			—
Intl			—						—						—			—			—
WW			592						625						(5.2)			(5.2)			—
OTHER
US			121						139						(12.2)			(12.2)			—
Intl			170						194						(11.9)			(10.0)			(1.9)
WW			292						332						(12.0)			(10.9)			(1.1)
TOTAL INNOVATIVE MEDICINE
US			8,871						8,249						7.5			7.5			—
Intl			5,709						5,644						1.2			4.4			(3.2)
WW			$	14,580					13,893						4.9		%	6.3		%	(1.4)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			THIRD QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR(4)
US			$	1,148					891						28.6		%	28.6		%	—		%
Intl			819						667						22.8			23.7			(0.9)
WW			1,966						1,558						26.2			26.5			(0.3)
ELECTROPHYSIOLOGY
US			660						611						7.9			7.9			—
Intl			619						549						12.7			13.8			(1.1)
WW			1,279						1,161						10.2			10.7			(0.5)
ABIOMED
US			293						254						15.4			15.4			—
Intl			68						57						20.1			20.1			0.0
WW			362						311						16.3			16.3			0.0
SHOCKWAVE(5)
US			163						—						*			*			—
Intl			66						—						*			*			—
WW			229						—						*			*			—
OTHER CARDIOVASCULAR(4)
US			30						26						16.7			16.7			—
Intl			66						61						7.7			7.5			0.2
WW			96						87						10.4			10.2			0.2
ORTHOPAEDICS
US			1,359						1,349						0.7			0.7			—
Intl			832						815						2.0			2.2			(0.2)
WW			2,191						2,164						1.2			1.3			(0.1)
HIPS
US			250						239						4.8			4.8			—
Intl			131						136						(3.6)			(3.2)			(0.4)
WW			381						375						1.7			1.9			(0.2)
KNEES
US			212						207						2.2			2.2			—
Intl			140						131						6.9			7.0			(0.1)
WW			352						338						4.0			4.1			(0.1)
TRAUMA
US			497						488						1.8			1.8			—
Intl			265						253						4.2			4.8			(0.6)
WW			761						742						2.6			2.8			(0.2)
SPINE, SPORTS & OTHER
US			400						415						(3.6)			(3.6)			—
Intl			296						295						0.4			0.4			0.0
WW			696						710						(1.9)			(2.0)			0.1

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			THIRD QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US			$983						994						(1.1)		%	(1.1)		%	—		%
Intl			1,451						1,483						(2.2)			(0.3)			(1.9)
WW			2,434						2,479						(1.8)			(0.7)			(1.1)
ADVANCED
US			448						455						(1.4)			(1.4)			—
Intl			661						709						(6.8)			(5.1)			(1.7)
WW			1,109						1,164						(4.7)			(3.6)			(1.1)
GENERAL
US			535						540						(0.9)			(0.9)			—
Intl			791						775						2.1			4.0			(1.9)
WW			1,325						1,314						0.8			2.0			(1.2)
VISION
US			549						512						7.2			7.2			—
Intl			751						744						0.9			1.8			(0.9)
WW			1,300						1,256						3.5			4.0			(0.5)
CONTACT LENSES / OTHER
US			441						399						10.2			10.2			—
Intl			527						529						(0.3)			0.6			(0.9)
WW			968						928						4.2			4.7			(0.5)
SURGICAL
US			108						112						(3.6)			(3.6)			—
Intl			225						216						3.9			4.7			(0.8)
WW			333						328						1.3			1.9			(0.6)
TOTAL MEDTECH
US			4,038						3,747						7.8			7.8			—
Intl			3,853						3,711						3.9			5.0			(1.1)
WW			$7,891						7,458						5.8		%	6.4		%	(0.6)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			NINE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)
IMMUNOLOGY
US			$8,499						8,506						(0.1)		%	(0.1)		%	—		%
Intl			5,090						4,951						2.8			7.3			(4.5)
WW			13,590						13,457						1.0			2.6			(1.6)
REMICADE
US			778						849						(8.5)			(8.5)			—
US Exports(3)			89						112						(20.5)			(20.5)			—
Intl			380						449						(15.4)			(11.3)			(4.1)
WW			1,246						1,410						(11.6)			(10.3)			(1.3)
SIMPONI / SIMPONI ARIA
US			820						866						(5.3)			(5.3)			—
Intl			787						829						(5.1)			4.1			(9.2)
WW			1,607						1,695						(5.2)			(0.7)			(4.5)
STELARA
US			5,021						5,180						(3.1)			(3.1)			—
Intl			2,991						2,925						2.2			5.4			(3.2)
WW			8,012						8,105						(1.2)			0.0			(1.2)
TREMFYA
US			1,789						1,490						20.1			20.1			—
Intl			932						747						24.7			29.6			(4.9)
WW			2,721						2,237						21.6			23.3			(1.7)
OTHER IMMUNOLOGY
US			3						9						(66.8)			(66.8)			—
Intl			0						0						—			—			—
WW			3						9						(66.8)			(66.8)			—
INFECTIOUS DISEASES
US			1,023						1,147						(10.8)			(10.8)			—
Intl			1,599						2,420						(33.9)			(33.4)			(0.5)
WW			2,622						3,566						(26.5)			(26.1)			(0.4)
COVID-19 VACCINE
US			0						0						—			—			—
Intl			198						1,073						(81.6)			(81.6)			0.0
WW			198						1,073						(81.6)			(81.6)			0.0
EDURANT / rilpivirine
US			24						26						(10.0)			(10.0)			—
Intl			926						816						13.5			13.3			0.2
WW			950						843						12.7			12.6			0.1
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US			990						1,105						(10.5)			(10.5)			—
Intl			315						310						1.8			4.3			(2.5)
WW			1,305						1,415						(7.8)			(7.2)			(0.6)
OTHER INFECTIOUS DISEASES
US			10						15						(37.7)			(37.7)			—
Intl			160						220						(27.4)			(24.2)			(3.2)
WW			169						235						(28.0)			(25.1)			(2.9)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			NINE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
NEUROSCIENCE
US			$3,250						3,043						6.8		%	6.8		%	—		%
Intl			2,090						2,296						(8.9)			(4.8)			(4.1)
WW			5,340						5,339						0.0			1.8			(1.8)
CONCERTA / methylphenidate
US			101						191						(47.5)			(47.5)			—
Intl			382						412						(7.3)			(2.9)			(4.4)
WW			482						603						(20.0)			(17.0)			(3.0)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US			2,329						2,164						7.6			7.6			—
Intl			830						940						(11.7)			(8.7)			(3.0)
WW			3,159						3,104						1.8			2.7			(0.9)
SPRAVATO
US			660						409						61.2			61.2			—
Intl			120						74						62.9			65.0			(2.1)
WW			780						483						61.5			61.8			(0.3)
OTHER NEUROSCIENCE
US			161						278						(42.1)			(42.1)			—
Intl			759						870						(12.8)			(7.4)			(5.4)
WW			920						1,149						(19.9)			(15.8)			(4.1)
ONCOLOGY
US			7,835						6,177						26.8			26.8			—
Intl			7,450						6,865						8.5			12.6			(4.1)
WW			15,284						13,043						17.2			19.3			(2.1)
CARVYKTI
US			565						324						74.6			74.6			—
Intl			63						17						*			*			*
WW			629						341						84.3			84.2			0.1
DARZALEX
US			4,789						3,882						23.4			23.4			—
Intl			3,797						3,312						14.6			19.9			(5.3)
WW			8,586						7,194						19.3			21.8			(2.5)
ERLEADA
US			940						778						20.8			20.8			—
Intl			1,275						961						32.6			35.6			(3.0)
WW			2,215						1,740						27.3			29.0			(1.7)
IMBRUVICA
US			770						796						(3.2)			(3.2)			—
Intl			1,537						1,681						(8.5)			(6.1)			(2.4)
WW			2,307						2,476						(6.8)			(5.2)			(1.6)
TECVAYLI
US			310						232						34.0			34.0			—
Intl			93						37						*			*			*
WW			403						269						49.6			50.0			(0.4)
ZYTIGA / abiraterone acetate
US			25						41						(38.0)			(38.0)			—
Intl			470						646						(27.1)			(22.8)			(4.3)
WW			496						686						(27.8)			(23.7)			(4.1)
OTHER ONCOLOGY
US			435						125						*			*			—
Intl			214						211						2.0			4.8			(2.8)
WW			649						336						93.4		%	95.1		%	(1.7)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			NINE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
PULMONARY HYPERTENSION
US			$	2,324					1,964						18.4		%	18.4		%	—		%
Intl			866						835						3.7			10.6			(6.9)
WW			3,190						2,798						14.0			16.1			(2.1)
OPSUMIT
US			1,135						924						22.8			22.8			—
Intl			504						512						(1.6)			2.2			(3.8)
WW			1,639						1,437						14.1			15.4			(1.3)
UPTRAVI
US			1,120						978						14.5			14.5			—
Intl			232						185						25.5			33.5			(8.0)
WW			1,352						1,163						16.3			17.5			(1.2)
OTHER PULMONARY HYPERTENSION
US			70						61						14.0			14.0			—
Intl			129						137						(5.8)			10.9			(16.7)
WW			199						199						0.3			11.9			(11.6)
CARDIOVASCULAR / METABOLISM / OTHER
US			2,061						2,254						(8.5)			(8.5)			—
Intl			543						580						(6.4)			(4.6)			(1.8)
WW			2,605						2,834						(8.1)			(7.7)			(0.4)
XARELTO
US			1,697						1,840						(7.8)			(7.8)			—
Intl			—						—						—			—			—
WW			1,697						1,840						(7.8)			(7.8)			—
OTHER
US			364						414						(11.9)			(11.9)			—
Intl			543						580						(6.4)			(4.6)			(1.8)
WW			908						994						(8.7)			(7.7)			(1.0)
TOTAL INNOVATIVE MEDICINE
US			24,993						23,090						8.2			8.2			—
Intl			17,639						17,947						(1.7)			2.1			(3.8)
WW			$	42,632					41,037						3.9		%	5.5		%	(1.6)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			NINE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR(4)
US			$	3,292					2,662						23.6		%	23.6		%	—		%
Intl			2,353						2,019						16.5			20.5			(4.0)
WW			5,645						4,681						20.6			22.3			(1.7)
ELECTROPHYSIOLOGY
US			2,057						1,791						14.8			14.8			—
Intl			1,889						1,658						14.0			18.2			(4.2)
WW			3,946						3,449						14.4			16.5			(2.1)
ABIOMED
US			905						790						14.5			14.5			—
Intl			207						176						17.7			20.0			(2.3)
WW			1,112						966						15.1			15.5			(0.4)
SHOCKWAVE(5)
US			240						—						*			*			—
Intl			66						—						*			*			—
WW			306						—						*			*			—
OTHER CARDIOVASCULAR(4)
US			89						81						10.6			10.6			—
Intl			192						186						3.0			5.7			(2.7)
WW			281						267						5.3			7.2			(1.9)
ORTHOPAEDICS
US			4,229						4,100						3.2			3.2			—
Intl			2,614						2,574						1.5			3.1			(1.6)
WW			6,843						6,674						2.5			3.2			(0.7)
HIPS
US			785						730						7.5			7.5			—
Intl			435						432						0.6			2.4			(1.8)
WW			1,220						1,162						5.0			5.6			(0.6)
KNEES
US			684						654						4.5			4.5			—
Intl			463						415						11.5			12.7			(1.2)
WW			1,147						1,069						7.2			7.7			(0.5)
TRAUMA
US			1,499						1,462						2.5			2.5			—
Intl			786						775						1.4			3.0			(1.6)
WW			2,285						2,238						2.1			2.7			(0.6)
SPINE, SPORTS & OTHER
US			1,262						1,254						0.6			0.6			—
Intl			930						952						(2.3)			(0.6)			(1.7)
WW			2,191						2,205						(0.6)			0.1			(0.7)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			NINE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US			$2,965						2,984						(0.6)		%	(0.6)		%	—		%
Intl			4,373						4,522						(3.3)			0.4			(3.7)
WW			7,338						7,507						(2.2)			0.0			(2.2)
ADVANCED
US			1,360						1,365						(0.4)			(0.4)			—
Intl			1,977						2,139						(7.6)			(4.2)			(3.4)
WW			3,337						3,504						(4.8)			(2.7)			(2.1)
GENERAL
US			1,605						1,619						(0.9)			(0.9)			—
Intl			2,397						2,383						0.6			4.4			(3.8)
WW			4,001						4,002						0.0			2.3			(2.3)
VISION
US			1,619						1,599						1.3			1.3			—
Intl			2,224						2,265						(1.8)			1.0			(2.8)
WW			3,843						3,864						(0.5)			1.1			(1.6)
CONTACT LENSES / OTHER
US			1,288						1,252						2.8			2.8			—
Intl			1,508						1,568						(3.8)			(0.4)			(3.4)
WW			2,796						2,820						(0.9)			1.0			(1.9)
SURGICAL
US			331						346						(4.4)			(4.4)			—
Intl			717						698						2.7			4.2			(1.5)
WW			1,048						1,044						0.3			1.4			(1.1)
TOTAL MEDTECH
US			12,105						11,345						6.7			6.7			—
Intl			11,564						11,382						1.6			4.7			(3.1)
WW			$23,669						22,727						4.1		%	5.7		%	(1.6)		%

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

*    Percentage greater than 100% or not meaningful

(1)Operational growth excludes the effect of translational currency

(2)Unaudited

(3)Reported as U.S. sales

(4)Previously referred to as Interventional Solutions

(5)Acquired on May 31, 2024

---

Supplemental sales information (unaudited)

(Dollars in Millions)

						THIRD QUARTER
																		% Change
						2024						2023						Total			Operations			Currency
Innovative Medicine
U.S.						$	8,871					8,249						7.5		%	7.5			—
International						5,709						5,644						1.2			4.4			(3.2)
Worldwide						14,580						13,893						4.9			6.3			(1.4)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						1						41						(97.7)			(98.9)			1.2
Worldwide						1						41						(97.7)			(98.9)			1.2
Innovative Medicine excluding COVID-19 Vaccine
U.S.						8,871						8,249						7.5			7.5			—
International						5,708						5,603						1.9			5.2			(3.3)
Worldwide						14,579						13,852						5.2			6.6			(1.4)
Worldwide
U.S.						12,909						11,996						7.6			7.6			—
International						9,562						9,355						2.2			4.6			(2.4)
Worldwide						22,471						21,351						5.2			6.3			(1.1)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						1						41						(97.7)			(98.9)			1.2
Worldwide						1						41						(97.7)			(98.9)			1.2
Worldwide
U.S.						12,909						11,996						7.6			7.6			—
International						9,561						9,314						2.7			5.1			(2.4)
Worldwide excluding COVID-19 Vaccine						$	22,470					21,310						5.4			6.5			(1.1)
Europe						$	4,914					4,727						4.0		%	3.0			1.0
Europe COVID-19 Vaccine Sales						1						41						(97.7)			(98.9)			1.2
Europe excluding COVID-19 Vaccine						$	4,913					4,686						4.8		%	3.8			1.0

Note: Columns and rows within tables may not add due to rounding

---

Supplemental sales information (unaudited)

(Dollars in Millions)

						NINE MONTHS
																		% Change
						2024						2023						Total			Operations			Currency
Innovative Medicine
U.S.						$	24,993					23,090						8.2		%	8.2			—
International						17,639						17,947						(1.7)			2.1			(3.8)
Worldwide						42,632						41,037						3.9			5.5			(1.6)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						198						1,073						(81.6)			(81.6)			0.0
Worldwide						198						1,073						(81.6)			(81.6)			0.0
Innovative Medicine excluding COVID-19 Vaccine
U.S.						24,993						23,090						8.2			8.2			—
International						17,441						16,874						3.4			7.4			(4.0)
Worldwide						42,434						39,964						6.2			7.9			(1.7)
Worldwide
U.S.						37,098						34,435						7.7			7.7			—
International						29,203						29,329						(0.4)			3.1			(3.5)
Worldwide						66,301						63,764						4.0			5.6			(1.6)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						198						1,073						(81.6)			(81.6)			0.0
Worldwide						198						1,073						(81.6)			(81.6)			0.0
Worldwide
U.S.						37,098						34,435						7.7			7.7			—
International						29,005						28,256						2.7			6.3			(3.6)
Worldwide excluding COVID-19 Vaccine						$	66,103					62,691						5.4		%	7.1			(1.7)
Europe						$	15,291					15,448						(1.0)		%	(0.7)			(0.3)
Europe COVID-19 Vaccine Sales						198						1,073						(81.6)			(81.6)			—
Europe excluding COVID-19 Vaccine						$	15,093					14,375						5.0		%	5.3			(0.3)

Note: Columns and rows within tables may not add due to rounding